LPOXY initiates $28M Series A financing with 5 Horizons Ventures to fund pivotal trial
September 4, 2025 | Startland News Staff
PLATTE CITY, Mo. — Funding to secure the upcoming trial of a Missouri biopharmaceutical company’s solution for preventing a deadly gut infection could prove critical in the fight against a condition that claims 80 U.S. lives daily, said Dr. Larry Sutton.
LPOXY Therapeutics, which is developing a novel non-antibiotic therapy to prevent Clostridioides difficile infections (Cdiff), announced Wednesday it has signed a term sheet with 5Horizons Ventures, a life science venture capital firm focused on innovative healthcare solutions in support of a $28 million Series A financing.
Elevator pitch: LPOXY Therapeutics is transforming infection prevention with a first-in-class oral therapeutic aimed at preventing C. difficile colitis, a CDC-designated urgent public health threat that kills over 80 Americans every day. Our unique approach delivers oxygen directly to the gut, creating an environment hostile to C. difficile bacteria without using antibiotics.
The agreement facilitates the formation of an investment syndicate to fund LPOXY’s registrational STOP-Cdiff (SIDIPREV Trial On Prevention of C. difficile Infections) clinical trial.
“5 Horizons Ventures’ commitment marks a major milestone for LPOXY as we move toward launching our pivotal STOP-Cdiff trial,” said Sutton, CEO and co-founder of LPOXY, one of Startland News’ 10 Kansas City Startups to Watch in 2025. “SIDIPREV represents a novel approach to infection prevention that not only addresses a deadly unmet need but also aligns with hospital economics by reducing costly complications within fixed DRG payments.”
ICYMI: LPOXY Therapeutics punches back at gut infection (and a foe with a billion-year head start)
The upcoming trial is designed under the FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs guidance and is intended to serve as the registrational study for SIDIPREV™, a therapy that aims to prevent life-threatening Cdiff in high-risk hospitalized patients. C. difficile is categorized by the CDC as an urgent public health threat that kills 80 Americans every day.
SIDIPREV is an orally administered, enteric-coated capsule that releases a metered dose of oxygen into the lower gastrointestinal tract, creating an environment hostile to anaerobic pathogens like C. difficile. Oxygen also suppresses toxin production and has mucosal anti-inflammatory effects.
As planned, STOP-Cdiff is a randomized, placebo-controlled superiority trial that will evaluate the efficacy and safety of SIDIPREV in approximately 500 hospitalized patients at elevated risk for Cdiff due to age and antibiotic exposure. LPOXY aims to launch the trial in Q3 2026 and file for approval in 2029.
“We’re impressed by the LPOXY team, their data, and their clear-eyed strategy for succeeding where many anti-infective programs have struggled,” said Paul Ferguson, partner and CFO of 5 Horizons Ventures. “SIDIPREV avoids the reimbursement and resistance-related hurdles that have plagued traditional antibiotics, making this a rare opportunity to unlock real economic value for patients, hospitals, and investors.”
LPOXY is actively building its investment syndicate and is in discussions with other institutional investors aligned with its late-stage clinical strategy.
2025 Startups to Watch
stats here
Related Posts on Startland News
KCPS superintendent to city struggling with violence: When do we all come together?
It’s inexcusable for Kansas City to simply accept 130 murders before it’s even December, Mark Bedell said. “Who do you think are committing these crimes?” Bedell, superintendent of Kansas City Public Schools, asked a crowd gathered Thursday for the Lean Lab’s Launch[ED) Day. “Probably people who have been victims of schools that have failed them…
Kauffman Foundation rolls out $1.2M microlending program to help underserved entrepreneurs
Amid a swarm of 160 events as part of Global Entrepreneurship Week, the Ewing Marion Kauffman Foundation announced a new microlending program to spur investment in underserved entrepreneurs. In partnership with four microfinance lenders, the foundation issued a series of grants totaling $1.2 million that a will change the way the nonprofit microlenders capitalize their…
Scared away from networking events? Anti-social introverts can turn to tech
Networking strength comes in numbers — even for anti-social introverts, Jeremy A. Smith told a crowd Tuesday at Global Entrepreneurship Week. “Anti-social people, myself included, hate events,” he said. But like all other entrepreneurs, such introverts still must build and maintain actionable professional networks from which they can request and receive value, Smith said. In-person networking…
Longfellow Farm coworking the soil amid KC’s urban food desert
In a city ripe with coworking office spaces, there’s a hunger for similar environments outdoors, Ami Freeberg said. As with maintaining individual workplaces, traditional urban farming also can be isolating and expensive, the Longfellow Farm manager said. By working together, however, the collaborative process allows for shared resources, greater human expertise and, of course, more…